Interstitial lung disease due to anti-TNF use in the treatment of psoriasis^☆☆

Abstract

Psoriasis is a chronic inflammatory disease that affects the skin variably, according to genetic and environmental factors. Some patients may benefit from systemic treatment with immunobiological agents, drugs that can be accompanied by several adverse effects. A case of a 58-year-old patient undergoing treatment for psoriasis with adalimumab for five years is reported. Alterations compatible with interstitial pneumonia were detected with important regression after adalimumab discontinuation. This case is relevant due to the scarcity of reports on late pulmonary adverse effect of anti-TNF treatment of psoriasis.

KEYWORDS
Adalimumab; Interstitial lung diseases; Psoriasis

Introduction

Psoriasis is characterized by the World Health Organization (WHO) as a systemic, non-contagious, inflammatory, and incapacitating disease, for which there is no cure. Systemic treatment is required in 20% to 30% of patients.¹ Being highly stigmatizing, the impact of psoriasis extends far beyond the body surface, affecting the individuals’ social relationships and personality.²

One of the main focal points of psoriasis research has been the development of biological therapies for this disease. Adalimumab is the first anti-human tumor necrosis factor (TNF) monoclonal antibody fully developed for the treatment of psoriasis and other immune-mediated diseases.³ However, varying adverse effects have been identified in patients treated with biological agents.⁴ Recently, cases have been reported associating the use of TNF-alpha inhibitors infliximab and etanercept to interstitial lung disease.⁵ However, the literature is scarce regarding the correlation between the use of adalimumab for the treatment of psoriasis and the subsequent development of interstitial pneumonia and this motivated the present report.

Case report

A 58-year-old patient, had been undergoing dermatological follow-up for plaque psoriasis for ten years. The patient had been well controlled during the last 5 years with the use of adalimumab (Humira™), receiving a dose of 40 mg every 14 days. Chest X-ray and PPD test were performed for annual screening due to the use of an immunobiological agent. Parietal thickening was observed in the posterior basal segments of the lung on the chest radiography, which prompted the case investigation.

The patient was asymptomatic from the respiratory point of view. On physical examination, there were rales in the pulmonary bases, bilaterally, without any other alterations. A chest computed tomography (CT) was performed (Fig. 1), with the following results: bilateral pulmonary infiltrate characterized by ground-glass opacities and a thin reticulation with basal predominance. Nodular and ground-glass opacities with sparse lobular center distribution were observed, which were more evident in the middle lobe.

Figure 1
Bilateral pulmonary infiltration characterized by ground-glass opacities and fine reticulation with a basal predominance. Nodular and ground-glass opacities with sparse centrilobular distribution, more evident in the middle lobe.

Adalimumab was discontinued due to the hypothesis of drug-induced pulmonary tuberculosis or interstitial pneumopathy. The patient denied having had contact with individuals with respiratory symptoms. A bronchoscopy was performed with bronchial lavage and culture, bacterioscopy, fungoscopy and AFB testing, which were all negative. Then, the hypothesis of infectious etiology was ruled out and a new chest CT was requested (Fig. 2) three months after the medication was discontinued, which showed sparse reticulonodular opacities in the lung parenchyma bilaterally, more evident in the lower lung fields, with partial resolution in comparison to the previous CT.

Figure 2
Sparse reticulonodular opacities in the pulmonary parenchyma bilaterally, more evident in the lower pulmonary fields. In comparison to the previous examination, partial resolution of the opacities was observed.

Due to the significant reduction in pulmonary infiltration after adalimumab discontinuation and without any other additional therapy, the dermatologists and the pulmonologist concluded that the causal relationship was sufficient for the diagnosis. One year after adalimumab discontinuation, the patient is using ustekinumab.

Discussion

The use of tumor necrosis factor (TNF) inhibitors in chronic inflammatory diseases has been well reported, showing that they are safe drugs, with pneumonia being observed as an adverse effect in 1.8% of cases.^4,5 Among the cases of interstitial pneumonia resulting from the use of immunobiological agents, about 97% are related to TNF-alpha inhibitors. In 89% of cases, patients suffered from psoriatic arthritis, and the pulmonary disease appeared approximately 26 weeks after starting the treatment.⁶ Therefore, the atypical and late presentation of this adverse effect is evident after 5 years of adalimumab use.

In psoriasis with solely cutaneous involvement, adalimumab has shown no significant difference when compared to placebo, regarding adverse effects.⁷ In countries such as Japan, the dose indicated for the treatment of psoriasis with adalimumab varies between 40 and 80 mg a week, with no significant adverse effects.⁸ The reported case is noteworthy, as the patient had the cutaneous form of psoriasis, did not use the maximum dose, and nevertheless developed interstitial lung disease due to the use of anti-TNF-alpha.

Ustekinumab (Stelara^™), a human IgG1 monoclonal antibody specific for IL-12/23, is also one of the most widely used drugs for the treatment of paradoxical psoriasis cases, which has been shown to be an effective alternative drug.⁹

This report reinforces the need for special care in relation to the monitoring of immunobiological agent users, whose screening with relevant tests and at the appropriate time is essential for the early diagnosis of potentially severe diseases that may have an asymptomatic presentation.¹⁰

• ☆☆
  Study conducted at the Department of Medicine, Hospital Universitário Onofre Lopes, Natal, RN, Brazil.
• Financial support
  None declared.

References

• ¹
  Sociedade Brasileira de Dermatologia. Consenso Brasileiro de Psoríase 2012: Guias de avaliação e tratamento. 2. ed Rio deJaneiro: SBD; 2012.
• ²
  Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. 2010;29:10-5.
• ³
  Armesto S, Coto-Segura P, Mayorga J, Illaro A, Santos-Juanes J. Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: a retrospective study of 100 patients in daily practice. J Dermatolog Treat. 2015;26:49-53.
• ⁴
  Cohen JV, Capell BC, Kinniry PA, Epstein AL. Rapidly fatal pulmonary fibrosis in a patient with psoriatic arthritis treated with adalimumab. J Rheumatol. 2011;38:398-9.
• ⁵
  Schoe A, van der Laan-Baalbergen NE, Huizinga TW, Breedveld FC, van Laar JM. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum. 2006;55:157-9.
• ⁶
  Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41:256-64.
• ⁷
  Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2014;170:274-303.
• ⁸
  Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol. 2010;37:299-310.
• ⁹
  Pugliese D, Daperno M, Fiorino G, Savarino E, Mosso E, Biancone L. Reallife effectiveness of Ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study. Dig Liver Dis. 2019;51:972-7.
• ¹⁰
  Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M. Biologicsinduced autoimmune diseases. Curr Opin Rheumatol. 2013;25:56-64.

Publication Dates

• Publication in this collection
  02 Aug 2021
• Date of issue
  May-Jun 2021

History

• Received
  6 July 2020
• Accepted
  13 Aug 2020